Company Future Sales Volume: Ultragenyx Corp (RARE)

Public company logo of Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical (RARE) develops revolutionary therapies for rare pathologies, driving growth within untapped medical niches. The company's expected execution level demonstrates a development trend where the current parameter equals 0.73. The monopoly status of its drugs enables the company to maintain pricing power, while its reliance on external contractors minimizes capital expenditures associated with maintaining proprietary manufacturing plants.

Ultragenyx Pharmaceutical - RARE Company Future Revenue (period 07/04/2022 - 11/18/2026)

Financial and market metric breakdowns for Ultragenyx Pharma (RARE)

- current price and projected stock value:
- company stock exchange capitalization indicators:
Comprehensive company analysis:RARE Ultragenyx
Brand item of Ultragenyx Pharmaceutical Inc.

To identify fundamental benchmarks in the financial reporting of Ultragenyx Pharmaceutical (RARE), it is critical for investors to track projected revenue, which measures cash flow generation potential by calculating expected demand. By analyzing sales expectations for the company's products, one can confirm the business's resilience, where a patent monopoly in metabolic gene therapy eliminates price competition and guarantees stable revenue growth.

Direct competitors

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Sales Volume Beam Therapeutics Corp (BEAM)|SRPT (Sarepta Therapeutics) - Projected Sales Volume|Company Expected Sales Volume Twist Bioscience Corp TWST|Projected Sales Volume TXG|Projected Sales Volume intelliatx.com (NTLA)|Stoke Therapeutics - Company Future Sales Volume|BioLife Solutions Inc (BLFS) - Company Expected Sales Volume|wavelifesciences.com - Projected Sales Volume|Maze Therapeutics Corp (MAZE) - Company Future Sales Volume|SION: Projected Sales Volume|Company Revenue Forecast PRME|Company Projected Revenue Taysha Gene Therapies|Company Revenue Forecast QURE (uniQure)|Company Projected Revenue MeiraGTx (MGTX)|REGENXBIO Corp - Company Revenue Forecast|Company Projected Revenue Solid Biosciences SLDB|OCGN - Company Future Sales Volume|pacb.com - Projected Sales Volume|Benitec (BNTC) - Company Future Sales Volume|DSGN: Projected Sales Volume|RCKT - Company Future Sales|FDMT: Company Future Sales|Company Revenue Forecast LXEO (lexeotx.com)|Company Projected Revenue Korro Bio Inc. (KRRO)|Company Projected Revenue Volume EDIT|Projected Sales Volume SLN (Silence Therapeutics PLC)|Company Future Revenue PRQR|CDXS - Company Projected Revenue|SGMO (Sangamo Therapeutics) - Company Revenue Forecast|NAUT: Projected Sales Volume|Company Revenue Forecast MGX|DTIL (precisionbiosciences.com) - Projected Sales Volume|Company Revenue Forecast GBIO (Generation Bio Co.)|Company Projected Revenue Boundless Bio (BOLD)|Exicure - Company Revenue Forecast|Projected Sales Volume IMNN (imunon.com)|Company Future Sales Phio Pharmaceuticals (PHIO)|MBIO: Company Future Sales Volume|Company Future Revenue RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Company Projected Revenue|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume